Chelsea and Westminster Hospital NHS Foundation Trust
Trust Medicines Committee

Summary of Main Points from the Meeting held on Monday 8th December 2014

2. Minutes and Summary Notes from last meeting
The Minutes and Summary notes from the November 2014 meeting were approved and will be circulated.

3. Matters Arising
The Committee noted the matters arising from the previous meeting.

4. Formulary Applications
Full applications

- **Vedolizumab 300mg infusion (Entyvio®)**

Decision: Deferred
It was agreed that the item would be deferred for consideration when NICE have published their final document.

- **VSL#3® Powder**

Decision: Accepted
VSL#3® powder is a probiotic food supplement that has been accepted onto the formulary for use under the supervision of a gastroenterologist, following an IBD MDT. It is indicated for the maintenance of remission of ileoanal pouchitis in adults induced by antibiotics. Should GPs be asked to continue treatment, an application to the NWLIF would be required.

- **Fidaxomicin 200mg tablets**

Decision: Accepted
Fidaxomicin 200mg tablets was approved onto the formulary for the treatment of recurrent Clostridium difficile infection, as recommended in the 2013 Public Health England publication: *'Updated guidance on the management and treatment of Clostridium difficile infection'.* It is only intended for use upon specialist microbiology advice.

Individual funding requests (For noting)

- **Alitretinoin**

Decision: Noted
Previously approved by the Pharmacoeconomics Board for the management of a specific patient with Pityriasis rubra pilari. The CCG have reviewed the application and refused the IFR.

- **Dolutegravir**

Decision: Noted
Previously approved by the Pharmacoeconomics Board for the management of a specific ARV naïve patient on various psychotropics.

5. Trust Medicines Policy

- **No items**

6. Medicines Management

- **Shared Care Guidance for Low Weight Molecular Heparins (LMWH)**

Decision: Noted
Draft of LMWH Shared Cared Guidance presented to committee. Guidance aims to facilitate the safe and appropriate prescribing and supply of LMWH in primary care.

7. NICE TA Guidance

- **SSC1456b_NICE 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality**

Lenalidomide is recommended as an option, within its marketing authorisation, that is for treating transfusion-dependent anaemia caused by low or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality when other therapeutic options are insufficient of inadequate.
Action: For noting. Lenalidomide is already in the Formulary for use in line with NICE TA 322.

- **TA323 - Erythropoiesis-stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy (including review of TA142)**

This guidance replaces Epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment –induced anaemia (NICE technology appraisal guidance 142, issued May 2008). The review if epoetin alfa, epoetin beta and darbepoetin alfa for cancer treatment-induced anaemia has resulted in a change in the guidance.
Action: For noting. Epoetin is already in the Formulary for use in line with NICE TA 323.

- **TA 325 - Nalmefene for reducing alcohol consumption in people with alcohol dependence.**

Nalmefene should only be prescribed in conjunction with continuous psychosocial support and only initiated in patients who continue to have a high drinking risk level 2 weeks after initial assessment

Action: Not applicable to C&W. CNWL Lead Pharmacist will confirm whether if it is likely if they will be recommending any patients for initiation on nalmefene during acute Trust admissions, following their New Drugs Panel Meeting in February 2015.

- **TA326 - Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (review of NICE technology appraisal guidance 196)**

This guidance replaces Imatinib for the adjuvant treatment of gastrointestinal stromal tumours (NICE technology appraisal guidance 196, issued August 2010).
Action: Not applicable to C&W.

8. IVIG Update
Decision: Noted

- **IVIG requests**

There were 11 IVIG issues in November 2014, with 3 new requests:
- One for Toxic Shock Syndrome (Blue Indication)
- Two for ITP (Red Indication)

- **Notification about Vigam and Gammaplex Shortage**

The manufacturers of Vigam and Gammaplex have informed the DH CMU that due to further unforeseen circumstances they will be unable to meet current demand for the products. Pharmacy will regularly review the situation and any issues, will raise with manufacturers

9. Items for noting

- **Quarterly Controlled Drug Report Q2 2014/15**

Decision: Noted
Quarterly CD Report 2015/2015 Q2

- **Quarterly Controlled Drug Occurrence Report Q2 2014/15**

Decision: Noted
Quarterly CD Occurrence Report 2014/2015 Q2

- **MHRA Update - November 2014**

Decision: Noted
MHRA update for November 2014

- **Cancer Drugs Fund List Updated**

Decision: Noted
List of drugs approved by the National Cancer Drugs Fund for specified indications as of 24/10/2014.

10. Meeting minutes for noting

- **HIV Drugs Sub-committee meeting – October 2014**

Decision: Noted

- **Local Chemotherapy Group meeting – July 2014**

Decision: Noted

- **Antibiotic Steering Group meeting – November 2014**

Decision: Noted

13. Date of next meeting
Monday 9th March 2015: 8.00 - 9.00
Board Room: Lower Ground Floor, Lift Bank B
Closing date for papers: Friday 13th February